THE STATE OF LIFE SCIENCE

By Dennis MeredithTHE STATE OF LIFE SCIENCENorth Carolina combines academic, industrial, government, and private resources to drive research, development, and manufacturing A half century ago, the world was only beginning to grasp the stunning implications of Watson's and Crick's double-helix DNA structure. Amidst those earliest glimmerings of the genetic revolution, North Carolina was already laying the foundation for its 21st-century success in biotechnology. In 1959, however, the evidence o

Written byDennis Meredith
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

A half century ago, the world was only beginning to grasp the stunning implications of Watson's and Crick's double-helix DNA structure. Amidst those earliest glimmerings of the genetic revolution, North Carolina was already laying the foundation for its 21st-century success in biotechnology. In 1959, however, the evidence of North Carolina's ambitions consisted not of gleaming scientific laboratories, but only of 3,500 acres of dense pine forest. It was the daring plan of a cadre of academic, business, and government leaders to carve from that forest a vast Research Triangle Park (RTP) that would enlist the scientific talents of the area's universities, supported by government and private investment.

Today, RTP sprawls over 7,000 acres in roughly the center of the state. It includes 19 million square feet of facilities and 119 research and development organizations. The park, as well as the tradition of collaboration that nurtured it, sparked a powerful driving ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies